| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 150, 641-651, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
FO Nestle, G Burg, J Fah, T Wrone-Smith and BJ Nickoloff
Department of Dermatology, University of Zurich Medical School, Switzerland.
Immune surveillance of skin cancer involves the stimulation of effector T cells by tumor-derived antigens and antigen-presenting cells (APCs). An effective APC must not only display processed antigen in the context of MHC molecules but also express co-stimulatory molecules that are required to fully activate T cells. One of the most common cutaneous neoplasms is basal cell carcinoma. To investigate expression of the co- stimulatory molecules CD80 (B7-1) and CD86 (B7-2) on tumor-associated dendritic cells (TADCs), cryosections from basal cell carcinomas were immunostained. In basal cell carcinomas, only 1 to 2% of intratumor and 5 to 10% of peritumor APCs expressed CD80 or CD86. In contrast, biopsies of immunological/inflammatory dermatoses revealed that 38 to 73% of APCs expressed CD80 and CD86. To further evaluate their phenotype and function, TADCs were isolated from tissue samples of basal cell carcinomas; they were non-adherent to plastic, displayed a typical dendritic morphology, and expressed high levels of major histocompatibility class II molecules on their surface. When TADCs were compared with dendritic cells from blood for presentation of superantigens (staphylococcal enterotoxins A and B) to resting autologous T cells, TADCs were consistently weaker stimulators of T cell proliferation than blood dendritic cells. When analyzed by flow cytometry, TADCs expressed high levels of HLA-DR, but only 5 to 10% co- expressed CD80 or CD86. A 3-day culture in granulocyte/macrophage colony-stimulating factor-containing medium partially reconstituted the TADC expression of CD80 and CD86 as well as their immunostimulatory capacity. Thus, in this common skin cancer, although there are prominent collections of HLA-DR-positive APCs in and around tumor cells, the TADCs are deficient in important co-stimulatory molecules as well as being weak stimulators of T cell proliferation. The paucity of co-stimulatory molecule expression and functional activity of TADCs may explain why the local T lymphocytic infiltrate fails to become fully activated to eradicate adjacent tumor cells. From a clinical perspective, these findings suggest a novel immunotherapeutic strategy targeting T cell co-stimulatory molecules on professional APCs in cutaneous oncology.
This article has been cited by other articles:
 |
|
 |
|
  J. Nemunaitis, R. O. Dillman, P. O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, A. Tong, P. Kumar, B. Pappen, C. Hamilton, et al. Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 10, 2006; 24(29): 4721 - 4730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. L. Tourkova, G. V. Shurin, G. S. Chatta, L. Perez, J. Finke, T. L. Whiteside, S. Ferrone, and M. R. Shurin Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides J. Immunol., September 1, 2005; 175(5): 3045 - 3052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gerlini, A. Tun-Kyi, C. Dudli, G. Burg, N. Pimpinelli, and F. O. Nestle Metastatic Melanoma Secreted IL-10 Down-Regulates CD1 Molecules on Dendritic Cells in Metastatic Tumor Lesions Am. J. Pathol., December 1, 2004; 165(6): 1853 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Engleman, J. Brody, and L. Soares Using Signaling Pathways to Overcome Immune Tolerance to Tumors Sci. Signal., July 13, 2004; 2004(241): pe28 - pe28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Monti, B. E. Leone, A. Zerbi, G. Balzano, S. Cainarca, V. Sordi, M. Pontillo, A. Mercalli, V. Di Carlo, P. Allavena, et al. Tumor-Derived MUC1 Mucins Interact with Differentiating Monocytes and Induce IL-10highIL-12low Regulatory Dendritic Cell J. Immunol., June 15, 2004; 172(12): 7341 - 7349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, P.-Y. Pan, P. Gu, D. Xu, and S.-H. Chen Role of Immature Myeloid Gr-1+ Cells in the Development of Antitumor Immunity Cancer Res., February 1, 2004; 64(3): 1130 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hartmann, B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres, and G. Hartmann Identification and Functional Analysis of Tumor-Infiltrating Plasmacytoid Dendritic Cells in Head and Neck Cancer Cancer Res., October 1, 2003; 63(19): 6478 - 6487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Urosevic, T. Maier, B. Benninghoff, H. Slade, G. Burg, and R. Dummer Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo Arch Dermatol, October 1, 2003; 139(10): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maier, A. Tun-Kyi, A. Tassis, K.-P. Jungius, G. Burg, R. Dummer, and F. O. Nestle Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells Blood, October 1, 2003; 102(7): 2338 - 2344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kleinhans, A. Tun-Kyi, M. Gilliet, M. E. Kadin, R. Dummer, G. Burg, and F. O. Nestle Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma Blood, February 15, 2003; 101(4): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Gabrilovich, P. Cheng, Y. Fan, B. Yu, E. Nikitina, A. Sirotkin, M. Shurin, T. Oyama, Y. Adachi, S. Nadaf, et al. H1{degrees} histone and differentiation of dendritic cells. A molecular target for tumor-derived factors J. Leukoc. Biol., August 1, 2002; 72(2): 285 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Sombroek, A. G. M. Stam, A. J. Masterson, S. M. Lougheed, M. J. A. G. Schakel, C. J. L. M. Meijer, H. M. Pinedo, A. J. M. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation J. Immunol., May 1, 2002; 168(9): 4333 - 4343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Merad, T. Sugie, E. G. Engleman, and L. Fong In vivo manipulation of dendritic cells to induce therapeutic immunity Blood, March 1, 2002; 99(5): 1676 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Halliday and S. Le Transforming growth factor-{beta} produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin Int. Immunol., September 1, 2001; 13(9): 1147 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Almand, J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer J. Immunol., January 1, 2001; 166(1): 678 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Almand, J. R. Resser, B. Lindman, S. Nadaf, J. I. Clark, E. D. Kwon, D. P. Carbone, and D. I. Gabrilovich Clinical Significance of Defective Dendritic Cell Differentiation in Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1755 - 1766. [Abstract] [Full Text]
|
|
|
|
|
|
D. I. Gabrilovich, T. Ishida, S. Nadaf, J. E. Ohm, and D. P. Carbone Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function Clin. Cancer Res., October 1, 1999; 5(10): 2963 - 2970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ohm, M. R. Shurin, C. Esche, M. T. Lotze, D. P. Carbone, and D. I. Gabrilovich Effect of Vascular Endothelial Growth Factor and FLT3 Ligand on Dendritic Cell Generation In Vivo J. Immunol., September 15, 1999; 163(6): 3260 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D. P. Carbone Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo Blood, December 1, 1998; 92(11): 4150 - 4166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishida, T. Oyama, D. P. Carbone, and D. I. Gabrilovich Defective Function of Langerhans Cells in Tumor-Bearing Animals Is the Result of Defective Maturation from Hemopoietic Progenitors J. Immunol., November 1, 1998; 161(9): 4842 - 4851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N.J. Hart Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response Blood, November 1, 1997; 90(9): 3245 - 3287. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
